Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Do cholinesterase inhibitors have disease-modifying effects in Alzheimer'sdisease?
Autore:
Giacobini, E;
Indirizzi:
Univ Geneva, Hosp Geneva, Dept Geriatr, Sch Med, CH-1226 Geneva, Switzerland Univ Geneva Geneva Switzerland CH-1226 Med, CH-1226 Geneva, Switzerland
Titolo Testata:
CNS DRUGS
fascicolo: 2, volume: 15, anno: 2001,
pagine: 85 - 91
SICI:
1172-7047(2001)15:2<85:DCIHDE>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
AMYLOID PRECURSOR PROTEIN; ACETYLCHOLINESTERASE ACTIVITY; CEREBROSPINAL-FLUID; CSF; PHYSOSTIGMINE; METRIFONATE; TACRINE; CORTEX; BRAIN; DOGS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Giacobini, E Univ Geneva, Hosp Geneva, Dept Geriatr, Sch Med, CH-1226 Geneva, Switzerland Univ Geneva Geneva Switzerland CH-1226 Geneva, Switzerland
Citazione:
E. Giacobini, "Do cholinesterase inhibitors have disease-modifying effects in Alzheimer'sdisease?", CNS DRUGS, 15(2), 2001, pp. 85-91

Abstract

During the last decade, a systematic effort to develop a pharmacological treatment for Alzheimer disease (AD) has resulted in drugs being registered for the first time in the US and Europe for this specific indication. The 3agents registered are cholinesterase inhibitors (ChEIs). The major therapeutic effect of ChEIs in patients with AD is the maintenance of cognitive function, as compared with placebo, during a B-month to 1-year period of treatment. Additional drug effects that may occur are the slowing of cognitive deterioration and improvement of behaviour and daily living activities. Comparison of clinical effects of 6 ChEIs demonstrates a rather similar magnitude of improvement in cognitive outcome measures. For some drugs, this level may represent an upper limit, while for others it may be possible to increase the benefit further. In order to maximise and prolong positive drug effects it is important to start treatment early and adjustthe dosage during treatment. Recent studies that used this administration strategy have shown that in many patients, the stabilisation effect produced by ChEIs can be prolonged for as long as 36 months. This long-lasting effect suggests mechanisms of action other than symptomatic ones. In this article, the effects of ChEIs on P-amyloid metabolism arepostulated to explain the stabilising (i.e. disease-modifying) effects of the drugs. Evidence for such a mechanism is available at the experimental but not yet at the clinical level.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 10:41:47